An exploratory study on optimizing the administration time of furquintinib combined with camrelizumab in the third-line treatment of MSS late colorectal cancer

ABSTRACT: Interventions: Test group:Camrelizumab + Fruquintinib Primary outcome(s): progression-free survival Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2716835 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR